{"pmid":32242829,"title":"One disease, different features: COVID-19 laboratory and radiological findings in three Italian patients.","text":["One disease, different features: COVID-19 laboratory and radiological findings in three Italian patients.","Clin Chem Lab Med","Tosato, Francesca","Giraudo, Chiara","Pelloso, Michela","Musso, Giulia","Piva, Elisa","Plebani, Mario","32242829"],"journal":"Clin Chem Lab Med","authors":["Tosato, Francesca","Giraudo, Chiara","Pelloso, Michela","Musso, Giulia","Piva, Elisa","Plebani, Mario"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32242829","week":"202014|Mar 30 - Apr 05","doi":"10.1515/cclm-2020-0319","keywords":["COVID-19","laboratory tests","radiological imaging"],"source":"PubMed","locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Diagnosis"],"weight":1,"_version_":1663079112898510848,"score":7.6048946,"similar":[{"pmid":32119647,"title":"Laboratory abnormalities in patients with COVID-2019 infection.","text":["Laboratory abnormalities in patients with COVID-2019 infection.","Clin Chem Lab Med","Lippi, Giuseppe","Plebani, Mario","32119647"],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Plebani, Mario"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32119647","week":"202010|Mar 02 - Mar 08","doi":"10.1515/cclm-2020-0198","keywords":["COVID-19","coronavirus","laboratory medicine","laboratory tests","prognosis"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663095626094608384,"score":83.07742},{"pmid":32172227,"title":"Laboratory abnormalities in children with novel coronavirus disease 2019.","text":["Laboratory abnormalities in children with novel coronavirus disease 2019.","Clin Chem Lab Med","Henry, Brandon Michael","Lippi, Giuseppe","Plebani, Mario","32172227"],"journal":"Clin Chem Lab Med","authors":["Henry, Brandon Michael","Lippi, Giuseppe","Plebani, Mario"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32172227","week":"202012|Mar 16 - Mar 22","doi":"10.1515/cclm-2020-0272","keywords":["COVID-19","Coronavirus","children","laboratory medicine","laboratory tests"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663095625957244929,"score":79.23841},{"pmid":32191623,"title":"The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks.","text":["The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks.","Coronavirus disease 2019, abbreviated to COVID-19 and sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the latest biological hazard to assume the relevance of insidious worldwide threat. One obvious question that is now engaging the minds of many scientists and healthcare professionals is whether and eventually how laboratory medicine could efficiently contribute to counteract this and other (future) viral outbreaks. Despite there being evidence that laboratory tests are vital throughout many clinical pathways, there are at least three major areas where in vitro diagnostics can also provide essential contributions to diagnostic reasoning and managed care of patients with suspected or confirmed SARS-CoV-2 infection. These include etiological diagnosis, patient monitoring, as well as epidemiologic surveillance. Nonetheless, some structural and practical aspects may generate substantial hurdles in providing timely and efficient response to this infectious emergency, which basically include inadequate (insufficient) environment and shortage of technical and human resources for facing enhanced volume of tests on many infected patients, some of whom are with severe disease. Some proactive and reactive strategies may hence be identified to confront this serious healthcare challenge, which entail major investments on conventional laboratory resources, reinforcement of regional networks of clinical laboratories, installation of mobile laboratories, as well as being proactive in establishing laboratory emergency plans.","Clin Chem Lab Med","Lippi, Giuseppe","Plebani, Mario","32191623"],"abstract":["Coronavirus disease 2019, abbreviated to COVID-19 and sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the latest biological hazard to assume the relevance of insidious worldwide threat. One obvious question that is now engaging the minds of many scientists and healthcare professionals is whether and eventually how laboratory medicine could efficiently contribute to counteract this and other (future) viral outbreaks. Despite there being evidence that laboratory tests are vital throughout many clinical pathways, there are at least three major areas where in vitro diagnostics can also provide essential contributions to diagnostic reasoning and managed care of patients with suspected or confirmed SARS-CoV-2 infection. These include etiological diagnosis, patient monitoring, as well as epidemiologic surveillance. Nonetheless, some structural and practical aspects may generate substantial hurdles in providing timely and efficient response to this infectious emergency, which basically include inadequate (insufficient) environment and shortage of technical and human resources for facing enhanced volume of tests on many infected patients, some of whom are with severe disease. Some proactive and reactive strategies may hence be identified to confront this serious healthcare challenge, which entail major investments on conventional laboratory resources, reinforcement of regional networks of clinical laboratories, installation of mobile laboratories, as well as being proactive in establishing laboratory emergency plans."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Plebani, Mario"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32191623","week":"202012|Mar 16 - Mar 22","doi":"10.1515/cclm-2020-0240","keywords":["COVID-19","coronavirus","laboratory medicine","laboratory tests"],"source":"PubMed","topics":["Diagnosis","Prevention"],"weight":1,"_version_":1662334543451914240,"score":76.547874},{"pmid":32239972,"title":"Differential Diagnosis for Coronavirus Disease (COVID-19): Beyond Radiologic Features.","text":["Differential Diagnosis for Coronavirus Disease (COVID-19): Beyond Radiologic Features.","AJR Am J Roentgenol","Lei, Pinggui","Fan, Bing","Wang, Pingxian","32239972"],"journal":"AJR Am J Roentgenol","authors":["Lei, Pinggui","Fan, Bing","Wang, Pingxian"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32239972","week":"202014|Mar 30 - Apr 05","doi":"10.2214/AJR.20.23119","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1662996001719320576,"score":50.99536},{"pmid":32232979,"title":"Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China.","text":["Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China.","An outbreak of SARS-CoV-2 epidemic spreads rapidly worldwide. SARS-CoV-2 infection caused mildly to seriously and fatally respiratory, enteric, cardiovascular, and neurological diseases. In this study, we detected and analyzed the main laboratory indicators related to heart injury, CK-MB, MYO, ultra-TnI and NT-proBNP, in 273 COVID-19 patients and investigated the correlation between heart injury and severity of the disease. It was found that higher concentration in venous blood of CK-MB, MYO, ultra-TnI and NT-proBNP were associated with the severity and case-fatality rate of COVID-19. Careful monitoring of the myocardiac enzyme profiles is of great importance in reducing the complications and mortality in COVID-19 patients. This article is protected by copyright. All rights reserved.","J Med Virol","Han, Huan","Xie, Linlin","Liu, Rui","Yang, Jie","Liu, Fang","Wu, Kailang","Chen, Lang","Hou, Wei","Feng, Yong","Zhu, Chengliang","32232979"],"abstract":["An outbreak of SARS-CoV-2 epidemic spreads rapidly worldwide. SARS-CoV-2 infection caused mildly to seriously and fatally respiratory, enteric, cardiovascular, and neurological diseases. In this study, we detected and analyzed the main laboratory indicators related to heart injury, CK-MB, MYO, ultra-TnI and NT-proBNP, in 273 COVID-19 patients and investigated the correlation between heart injury and severity of the disease. It was found that higher concentration in venous blood of CK-MB, MYO, ultra-TnI and NT-proBNP were associated with the severity and case-fatality rate of COVID-19. Careful monitoring of the myocardiac enzyme profiles is of great importance in reducing the complications and mortality in COVID-19 patients. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Han, Huan","Xie, Linlin","Liu, Rui","Yang, Jie","Liu, Fang","Wu, Kailang","Chen, Lang","Hou, Wei","Feng, Yong","Zhu, Chengliang"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232979","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25809","keywords":["COVID-19","disease severity","heart injury","laboratory indicators"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1662899337694281728,"score":50.577896}]}